title: Impaired FHIT expression characterizes serous ovarian carcinoma.
abstract: The FHIT (fragile histidine triad) gene on chromosome 3p14.2 is a candidate tumour suppressor gene. To define the role of the FHIT gene in the development of ovarian cancer, we have examined 33 ovarian carcinomas, 2 borderline tumours and 10 benign adenomas for the presence of FHIT gene alterations. FHIT transcripts were analysed by RT-PCR and sequencing. Aberrant FHIT transcripts were observed in 5/33 carcinomas (15%) and in 1 of 2 borderline tumours. Loss of normal FHIT transcript was observed in 5/33 carcinomas (15%) but not in 2 borderline tumours or 10 benign adenomas. Allelic losses at D3S1300 and D3S4103, both located within intron 5 of FHIT, were detected in 5/24 (21%) and 5/25 (20%) informative ovarian carcinomas, respectively. Expression of Fhit protein was analysed by immunohistochemistry in 44 carcinomas, 19 borderline tumours and 16 benign adenomas. Loss or significantly reduced expression of Fhit protein was observed in 6/44 (14%) ovarian carcinomas but not in any of 19 borderline tumours or 16 benign adenomas. The impaired Fhit protein expression was significantly correlated with the loss of normal FHIT transcription. Most notably, loss of normal FHIT transcript and impaired expression of Fhit protein occurred only in serous adenocarcinomas of grade 2 and 3 (5/15; 33% and 6/19; 32%, respectively). The present data suggest that inactivation of the FHIT gene by loss of expression is one of the important molecular events associated with the genesis of ovarian carcinoma, especially of high-grade serous carcinoma.
authors.affiliation: Department of Obstetrics and Gynecology, Osaka University Faculty of Medicine, Osaka, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ozaki
authors.forename: T
authors.initials: T
authors.lastname: Enomoto
authors.forename: K
authors.initials: K
authors.lastname: Yoshino
authors.forename: M
authors.initials: M
authors.lastname: Fujita
authors.forename: G S
authors.initials: GS
authors.lastname: Buzard
authors.forename: K
authors.initials: K
authors.lastname: Kawano
authors.forename: M
authors.initials: M
authors.lastname: Yamasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Murata
mesh_terms: D017766:Acid Anhydride Hydrolases; D000328:Adult; D000368:Aged; D000483:Alleles; D001483:Base Sequence; D015139:Blotting, Southern; D002893:Chromosomes, Human, Pair 3; D018284:Cystadenocarcinoma, Serous / Q000235:genetics*; D018293:Cystadenoma, Serous / Q000235:genetics*; D017931:DNA Primers; D018076:DNA, Complementary; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009363:Neoplasm Proteins; D010051:Ovarian Neoplasms / Q000235:genetics*; D011506:Proteins / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014158:Transcription, Genetic; D000099170:Bis(5'-adenosyl)triphosphatase
chemical_list: D017766:Acid Anhydride Hydrolases; D017931:DNA Primers; D018076:DNA, Complementary; D009363:Neoplasm Proteins; D011506:Proteins; D000099170:Bis(5'-adenosyl)triphosphatase